NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70934-0634-82 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 18, 2020 | Aug 31, 2023 | No Longer Used |
00006-3862-13 | 00006-3862 | Aprepitant | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Mar 26, 2003 | In Use | |||
25000-0011-27 | 25000-0011 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Apr 27, 2017 | In Use | |
54868-5738-01 | 54868-5738 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 29, 2006 | In Use | |
00781-1681-13 | 00781-1681 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Dec 1, 2015 | No Longer Used |
47335-0715-13 | 47335-0715 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 25, 2022 | No Longer Used | |
00069-0291-10 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
62856-0796-04 | 62856-0796 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct 13, 2014 | Oct 13, 2014 | No Longer Used |
70934-0634-84 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 13, 2021 | Jan 31, 2025 | No Longer Used |
00904-6552-61 | 00904-6552 | Ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
52125-0334-14 | 52125-0334 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug 11, 2014 | Apr 27, 2017 | No Longer Used |
55648-0186-01 | 55648-0186 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Mar 2, 2013 | In Use | ||
70934-0634-95 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 31, 2020 | May 31, 2025 | No Longer Used |
68788-8377-09 | 68788-8377 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 28, 2023 | In Use | |
00143-9384-01 | 00143-9384 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 8, 2020 | In Use | |
68001-0610-25 | 68001-0610 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Feb 28, 2024 | In Use | ||
68084-0399-11 | 68084-0399 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 24, 2012 | Jul 31, 2019 | No Longer Used |
00378-7732-05 | 00378-7732 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Oct 9, 2014 | No Longer Used |
69097-0927-35 | 69097-0927 | Palonosetron hydrochloride | Palonosetron hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Mar 23, 2018 | In Use | |
55390-0307-10 | 55390-0307 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 26, 2006 | Feb 28, 2011 | No Longer Used | |
00006-4109-06 | 00006-4109 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | May 6, 2011 | In Use |
67457-0920-05 | 67457-0920 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Oct 12, 2020 | May 31, 2021 | In Use | |
83980-0012-13 | 83980-0012 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 19, 2025 | In Use | |
00069-0700-12 | 00069-0700 | Ondansetron hydrochloride and dextrose | Ondansetron hydrochloride and dextrose | 32.0 mg/50mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 1, 2009 | Nov 1, 2012 | In Use |
70518-1042-00 | 70518-1042 | Ondansetron hydrochloride | Ondansetron hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 1, 2018 | May 11, 2020 | In Use |
Found 11765 results — Export these results